Biographical Sketch:
Dr. Potter was one of the early architects of the Alzheimer Disease Neuroimaging Initiative (ADNI), and he continues as former chair and active participant on the Industry Strategic Advisory Board.
Most recently, he served as Vice President of Translational Neuroscience at Merck Research Laboratories, prior to which he was head of early CNS development at Lilly Research Laboratories (1996-2004).
Before working in the pharmaceutical industry, Dr. Potter had a distinguished career at the National Institutes of Health (NIH), where in 1971 he began as a fellow in the laboratory of B. B. Brodie. During his 25 year career in the Public Health Service, mainly in the National Institutes of Mental Health (NIMH), he authored over 200 publications, won Distinguished Service and Alumni Awards, and was a mentor to numerous current chairs of departments in academia across US, Europe, South America and China, as well as senior executives in industry.
Dr. Potter received his undergraduate, graduate (pharmacology), and medical degrees from the University of Indiana and is board certified in Psychiatry. He served as Senior Surgeon and Medical Director in the US Military (1971-1995).
For the past 18 months he has served as co-chair of the Foundation of the National Institute of Health Biomarkers Consortium Neuroscience Steering Committee, where he has championed the collaborative development of both biochemical and cognitive measures to enhance drug development of Alzheimer’s and other brain diseases. In addition, he serves on the Institute of Medicine Forum on Neuroscience where he has organized and chaired public forums on such diverse topics as: suicidology and novel CNS biomarkers. As current Chair of the American College of Neuropsychopharmacology Goverument, Industry, Academia Liaison Committee, Dr. Potter focuses on opportunities to align and leverage efforts among stakeholders, and has recently been working with the leadership of both the Alzheimer’s Association and National Alliance for the Mentally III as representatives of patient concerns.
Dr. Potter’s current major interest is in seeing that everything possible is done to “realize the potential of methods that have been advanced over the last decade that allow one to better explore the physiological and biochemical processes associated with brain function, especially with regard to Alzheimer’s and other neurodegenerative diseases.
Topical Index:
Interview History:
Dates: Dec-03
Interviewer: T.Ban
Transcript:
Papers:
